Why not screen for subclinical atherosclerosis?

The Lancet

Volumn 378, Issue 9792, 2011, Pages 645-646

  Sillesen, Henrik ^a   Falk, Erling ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; HEALTH CARE COST; HEART INFARCTION; HUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL;

EID: 80052022090     PISSN: 0140-6736     EISSN: 1474-547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60059-7     Document Type: Note

References (12)

1. CJ Murray, JA Lauer, RC Hutubessy et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk Lancet 361 2003 717 725 (Pubitemid 36293625)
2. V Fuster, BM Mearns The CVD paradox: mortality vs prevalence Nat Rev Cardiol 6 2009 669
3. VL Roger, AS Go, DM Lloyd-Jones on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics - 2011 update: a report from the American Heart Association Circulation 123 2011 e18 209
4. M Naghavi, E Falk, HS Hecht for the SHAPE Task Force From vulnerable plaque to vulnerable patient - part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report Am J Cardiol 98 2006 2H 15H
5. PK Shah Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we? J Am Coll Cardiol 56 2010 98 105
6. P Muntendam, C McCall, J Sanz, E Falk, V Fuster for the High-Risk Plaque Initiative The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease - study design and objectives Am Heart J 160 2010 49 57
7. TA Manolio Genomewide association studies and assessment of the risk of disease N Engl J Med 363 2010 166 176
8. P Greenland, JS Alpert, GA Beller et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 56 2010 e50 103
9. AJ Taylor, M Cerqueira, JM Hodgson et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/ NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography J Am Coll Cardiol 56 2010 1864 1894
10. HS Hecht The deadly double standard (the saga of screening for subclinical atherosclerosis) Am J Cardiol 101 2008 1805 1807
11. MJ Pletcher, L Lazar, K Bibbins-Domingo et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering Ann Intern Med 150 2009 243 254
12. T Wisløff, OF Nordheim, S Halvorsen, RM Selmer, IS Kristiansen Costs and life year gained with pharmaceutical primary prevention of cardiovascular disease http://www.kunnskapssenteret.no/Publikasjoner/4786.cms Dec 18, 2008 (accessed Jan 3, 2011) (in Norwegian).